The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Inhibrx, Inc(NASDAQ:INBX) 
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarc...
Website: http://www.inhibrx.com
Founded: 2010
Full Time Employees: 75
CEO: Mark P. Lappe
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
Inhibrx Days Payable Outstanding ttm (DPO)
Inhibrx Days Receivable Outstanding ttm (DSO)
Inhibrx Days Inventory Outstanding ttm (DIO)
Inhibrx Op Cashflow Per Share ttm
Inhibrx Free Cashflow Per Share ttm
Inhibrx Cash Per Share ttm
Inhibrx P/S ratio ttm
Inhibrx (GAAP) P/E ratio ttm
Inhibrx P/B ratio ttm
No extra charts and metrics for this ticker.